Glucocorticoid facet joint injection for chronic back or neck pain

Scott Farrell; Ashley Smith; Byron Schneider; Geoff Schneider; Diane Grondin; Geoffrey Gelley; Pavlos Bobos; Christopher G Maher; Anita R Gross

doi:10.1002/14651858.CD015354

Glucocorticoid facet joint injection for chronic back or neck pain

Cochrane Database Syst Rev. 2024 Nov 21;11(11):CD015354. doi: 10.1002/14651858.CD015354.

Authors

Scott Farrell¹, Ashley Smith², Byron Schneider³, Geoff Schneider⁴, Diane Grondin⁵, Geoffrey Gelley⁶, Pavlos Bobos⁷, Christopher G Maher⁸, Anita R Gross⁹

Affiliations

¹ RECOVER Injury Research Centre & NHMRC Centre for Research Excellence: Better Health Outcomes for Compensable Injury, The University of Queensland, Brisbane, Australia.
² Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada.
³ Physical Medicine and Rehabilitation, Vanderbilt University, Tennessee, Kentucky, USA.
⁴ Cumming School of Medicine, University of Calgary, Calgary, Canada.
⁵ Canadian Memorial Chiropractic College, Toronto, Canada.
⁶ Private Practice, Gelley Chiropractic Clinic, Winnipeg, Canada.
⁷ Faculty of Health Sciences, Department of Health and Rehabilitation Sciences, Western University, London, Canada.
⁸ Sydney School of Public Health, University of Sydney, Sydney, Australia.
⁹ School of Rehabilitation Science, McMaster University, Hamilton, Canada.

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: The primary objective is to assess the benefits and harms of glucocorticoid facet joint injections in adults with chronic back or neck pain that is presumed to be facet joint-mediated. The secondary objective is to assess whether the effects differ by diagnostic method for facet joint-mediated pain.

Publication types

Systematic Review

MeSH terms

Adult
Back Pain* / drug therapy
Chronic Pain* / drug therapy
Glucocorticoids* / administration & dosage
Humans
Injections, Intra-Articular
Neck Pain* / drug therapy
Neck Pain* / etiology
Randomized Controlled Trials as Topic
Zygapophyseal Joint*

Substances

Glucocorticoids